Ono Enters Into A Research Collaboration Agreement With InveniAI

 


Ono Pharmaceutical Co., Ltd. has forged a research collaboration with InveniAI® LLC to uncover novel therapeutic targets, utilizing InveniAI's state-of-the-art artificial intelligence (AI) and machine learning (ML) technologies. The partnership involves the application of InveniAI's advanced platforms, AlphaMeld® and ChatAlphaMeldTM, integrating cutting-edge AI and ML algorithms, Generative AI tools, and large language modules. The objective is to identify therapeutic targets across various diseases specified by Ono and propose optimized drug discovery hypotheses. Ono will subsequently validate these hypotheses through studies, with exclusive global rights retained for the development and commercialization of resulting drug candidates.

Toichi Takino, Senior Executive Officer at Ono, acknowledges InveniAI's proprietary AI and ML technologies for identifying drug discovery mechanisms from extensive data, expressing expectations for significantly improved drug discovery research efficiency. The collaboration reflects Ono's commitment to providing innovative therapeutic options globally. Krishnan Nandabalan, President and CEO of InveniAI, highlights the partnership's potential to expedite the identification of de-risked product opportunities, emphasizing InveniAI's continuous integration of technological innovation to enhance patient outcomes, exemplified by the recent development of ChatAlphaMeldä, a transformative tool facilitating advanced technology utilization across the organization.

Read More - https://www.techdogs.com/tech-news/pr-newswire/ono-enters-into-a-research-collaboration-agreement-with-inveniai-to-identify-novel-therapeutic-targets

Comments

Popular posts from this blog

Varun Srinivas Founder & CEO of Therix.ai and Co-Founder at Coditas on Building Real-World AI Solutions

Education Technology Trends That Will Impact Your Business In 2025

Top 5 Marketing Automation Software Of 2025